Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting

Collecting economic data at the same time as evidence of effectiveness maximises the information available for analysis but requires proper consideration at the design stage

[1]  A. Gafni,et al.  An opportunity cost approach to sample size calculation in cost-effectiveness analysis. , 2008, Health economics.

[2]  C. Carswell.  Measuring and Valuing Health Benefits for Economic Valuation , 2007, PharmacoEconomics.

[3]  L. Davies.  ECONOMIC EVALUATION IN CLINICAL TRIALS , 1998 .

[4]  M. Drummond,et al.  Whither trial-based economic evaluation for health care decision making? , 2006, Health economics.

[5]  Anthony O'Hagan,et al.  Review of Statistical Methods for Analysing Healthcare Resources and Costs , 2010, Health economics.

[6]  S. Grosse.  Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold , 2008, Expert review of pharmacoeconomics & outcomes research.

[7]  David Feeny,et al.  Multi-Attribute Preference Functions , 1995, PharmacoEconomics.

[8]  Andrea Manca,et al.  Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies , 2005, International Journal of Technology Assessment in Health Care.

[9]  M. Sculpher,et al.  Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. , 2005, Health economics.

[10]  Dyfrig A Hughes,et al.  Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  A. Mcguire,et al.  Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. , 2000, Health economics.

[12]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[13]  R. Willke,et al.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  Brendan A. Rapple.  Payment by Results , 1994 .

[15]  Ann Netten,et al.  Unit Costs of Health and Social Care 2002 , 2000 .

[16]  M. Rahbar,et al.  Update on statistical power and sample size assessments for cost-effectiveness studies , 2004, Expert review of pharmacoeconomics & outcomes research.

[17]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[18]  A H Briggs,et al.  Power and Sample Size Calculations for Stochastic Cost-Effectiveness Analysis , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[19]  Stavros Petrou,et al.  Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting , 2011, BMJ : British Medical Journal.

[20]  Julia Earnshaw,et al.  NICE Guide to the Methods of Technology Appraisal , 2012, PharmacoEconomics.

[21]  G W Torrance,et al.  Multi-attribute preference functions. Health Utilities Index. , 1995, PharmacoEconomics.

[22]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[23]  R Mann,et al.  Methods to identify postnatal depression in primary care: an integrated evidence synthesis and value of information analysis. , 2009, Health technology assessment.

[24]  R. Edwards,et al.  Economic evaluation alongside pragmatic randomised trials: developing a standard operating procedure for clinical trials units , 2008, Trials.

[25]  Niklas Zethraeus,et al.  Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies , 2003, PharmacoEconomics.

[26]  G. Sanders,et al.  Cost-effectiveness as an outcome in randomized clinical trials , 2006, Clinical trials.

[27]  Discounting in decision making: the consistency argument revisited empirically. , 2004, Health policy.

[28]  R. Holman,et al.  Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) , 2005, Diabetologia.

[29]  Andrew Briggs,et al.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.

[30]  S. Thompson,et al.  How should cost data in pragmatic randomised trials be analysed? , 2000, BMJ : British Medical Journal.

[31]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.

[32]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[33]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[34]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[35]  A Briggs,et al.  Economic evaluation and clinical trials: size matters , 2000, BMJ : British Medical Journal.

[36]  D. Feeny,et al.  Utilities and Quality-Adjusted Life Years , 1989, International Journal of Technology Assessment in Health Care.

[37]  P. Dolan,et al.  Valuing health states: a comparison of methods. , 1996, Journal of health economics.

[38]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[39]  K. Schulman,et al.  Analytic considerations in economic evaluations of multinational cardiovascular clinical trials. , 2006, Value in Health.

[40]  D. Coyle,et al.  The Problem of Protocol Driven Costs in Pharmacoeconomic Analysis , 1998, PharmacoEconomics.

[41]  D. Elbourne,et al.  Cost-Effectiveness of Neonatal Extracorporeal Membrane Oxygenation Based on 7-Year Results From the United Kingdom Collaborative ECMO Trial , 2006, Pediatrics.

[42]  H. Kohli.  Scottish Medicines Consortium. , 2005, The National medical journal of India.

[43]  Stavros Petrou,et al.  Mapping analyses to estimate health utilities based on responses to the OM8-30 otitis media questionnaire , 2010, Quality of Life Research.

[44]  M. Kenward,et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.

[45]  Lelia Duley,et al.  Cost‐effectiveness of prophylactic magnesium sulphate for 9996 women with pre‐eclampsia from 33 countries: economic evaluation of the Magpie Trial , 2006, BJOG : an international journal of obstetrics and gynaecology.

[46]  Philip M Clarke,et al.  Optimal recall length in survey design. , 2008, Journal of health economics.

[47]  M. Drummond,et al.  Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[48]  Aki Tsuchiya,et al.  A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures , 2010, The European Journal of Health Economics.

[49]  P. Little,et al.  A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. , 2009 .

[50]  Kimbroe J. Carter,et al.  Treatment of Early-Stage Breast Cancer in the Elderly , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[51]  Sarah Wordsworth,et al.  Applied Methods of Cost-Effectiveness Analysis in Healthcare , 2010 .

[52]  T. Peters,et al.  Valuing the ICECAP capability index for older people. , 2008, Social science & medicine.

[53]  Philip D. Harvey,et al.  Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.